Once-weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2010 Apr 29

PMID 20425571

Citations 13

Authors

Mikkel Christensen

Filip K Knop

Affiliations

Soon will be listed here.

Abstract

Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.

Citing Articles

Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Rege N, Wickramasinghe N, Tustan A, Phillips N, Yee V, Ismail-Beigi F J Biol Chem. 2018; 293(28):10895-10910.

PMID: 29880646 PMC: 6052209. DOI: 10.1074/jbc.RA118.003650.

Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro.

Al-Dwairi A, Alqudah T, Al-Shboul O, Alqudah M, Mustafa A, Alfaqih M J Inflamm Res. 2018; 11:95-109.

PMID: 29593427 PMC: 5865574. DOI: 10.2147/JIR.S152835.

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.

Matza L, Boye K, Stewart K, Davies E, Paczkowski R BMC Health Serv Res. 2017; 17(1):774.

PMID: 29178918 PMC: 5702146. DOI: 10.1186/s12913-017-2648-7.

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

McBrayer D, Tal-Gan Y Drug Dev Res. 2017; 78(6):292-299.

PMID: 28786125 PMC: 5602594. DOI: 10.1002/ddr.21404.

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

Tahrani A, Barnett A, Bailey C Nat Rev Endocrinol. 2016; 12(10):566-92.

PMID: 27339889 DOI: 10.1038/nrendo.2016.86.

References

Nauck M, Duran S, Kim D, Johns D, Northrup J, Festa A . A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2006; 50(2):259-67. DOI: 10.1007/s00125-006-0510-2. View

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

Deacon C, Nauck M, Pridal L, Willms B, Holst J . Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44(9):1126-31. DOI: 10.2337/diab.44.9.1126. View

Klonoff D, Buse J, Nielsen L, Guan X, Bowlus C, Holcombe J . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2007; 24(1):275-86. DOI: 10.1185/030079908x253870. View

Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha I . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2008; 32(1):84-90. PMC: 2606836. DOI: 10.2337/dc08-1355. View

Okerson T, Yan P, Stonehouse A, Brodows R . Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2009; 23(3):334-9. DOI: 10.1038/ajh.2009.245. View

Meier J, Gethmann A, Gotze O, Gallwitz B, Holst J, Schmidt W . Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006; 49(3):452-8. DOI: 10.1007/s00125-005-0126-y. View

Egan J, Bulotta A, Hui H, Perfetti R . GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003; 19(2):115-23. DOI: 10.1002/dmrr.357. View

Heine R, Van Gaal L, Johns D, Mihm M, Widel M, Brodows R . Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143(8):559-69. DOI: 10.7326/0003-4819-143-8-200510180-00006. View

10.

Carraro-Lacroix L, Malnic G, Girardi A . Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009; 297(6):F1647-55. DOI: 10.1152/ajprenal.00082.2009. View

11.

Zhou J, Wang X, Pineyro M, Egan J . Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999; 48(12):2358-66. DOI: 10.2337/diabetes.48.12.2358. View

12.

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

13.

Bush M, Matthews J, De Boever E, Dobbins R, Hodge R, Walker S . Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009; 11(5):498-505. DOI: 10.1111/j.1463-1326.2008.00992.x. View

14.

Matthews J, Stewart M, De Boever E, Dobbins R, Hodge R, Walker S . Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(12):4810-7. DOI: 10.1210/jc.2008-1518. View

15.

Larsson H, Holst J, Ahren B . Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997; 160(4):413-22. DOI: 10.1046/j.1365-201X.1997.00161.x. View

16.

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

17.

Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen L, Rolan P . Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002; 25(8):1398-404. DOI: 10.2337/diacare.25.8.1398. View

18.

Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R . Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract. 2009; 15(4):326-34. DOI: 10.4158/EP09046.ORR. View

19.

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M . Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009; 32(10):1880-6. PMC: 2752910. DOI: 10.2337/dc09-0366. View

20.

Flint A, Raben A, Astrup A, Holst J . Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101(3):515-20. PMC: 508592. DOI: 10.1172/JCI990. View